FDA Endorsements, Strategic Partnerships, and Positive Trial Outcomes Lead This Week’s Health Sector Report

(RTTNews) – This week, the life‑science arena advanced with multiple U.S. Food and Drug Administration (FDA) and European Commission approvals, several high‑profile licensing agreements and mergers, and encouraging data from pivotal clinical trials across a range of therapeutic areas.

The highlights span pulmonary hypertension, obesity, hair loss, and cardiovascular disease, illustrating a broad spectrum of progress within the sector.

Below is a concise summary of the key events.

Regulatory Approvals

FDA Approvals and Rejections

Novartis Secures FDA Approval for Fabhalta in IgA Nephropathy

Novartis AG (NVS) received FDA approval for Fab suoiin ral.
Fabhalta (iptacopan) is the first complement inhibitor approved for adults with primary IgA nephropathy (IgAN) who are at risk of disease progression. The Phase 3 APPLAUSE‑IgAN trial demonstrated a reduction in estimated glomerular filtration rate decline and proteinuria, with a consistent safety profile. Fabhalta was previously approved for paroxysmal nocturnal hemoglobinuria in 2023 and received FDA authorization in March 2025 for adults with C3 glomerulopathy qay LLC,uote

NVS closed Friday’s trading on July 17, 2026 at $153.76, a 0.67 % uptick.

Merck Sec,targeted Age LIPFENDRA

Merck & Co. (MRK) achieved FDA approval for LIPFENDRA (enlicitide), a once‑daily oral PCSK9 inhibitor for adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). In the Phase 3 CORALreef study, LIPFENDRA reduced LDL‑C by up to 59 % versus placebo—a milestone in cholesterol management.

MRK closed Friday’s trading at $127.50, a slight decline of 0.10 %.

Nov Nordisk Gains EU Approval for Wegovy Pill

Novo Nordisk (NVO) obtained European Commission authorization for its once‑daily oral semaglutide 25 mg Wegovy capsule, designated for adults with obesity or overweight who have atPT; the OASIS Phase herman Phase 3 data showed weight loss averaging 17 % versus 3 % with placebo. One in three patients lost 20 % or more of their body weight.

NVO closed Friday’s trading at $50.32, down 2.能买吗%.

Celcuity Gets FDA Approval for REVTORPYK in Breast Cancer

Celcuity Inc. (CELC) secured FDA approval for REVTORPYK (gedatolisib), a targeted therapy for HR‑positive, HER2‑negative locally advanced or metastatic breast cancer without a PIK3CA mutation following endocrine‑resistant disease. Phase 3 VIKTORIA‑1 trial data showed a significant progression‑free survival benefit for both doublet and triple‑agent regimens.

CELC closed Friday’s trade at $88.38, a modest 0.10 % increase.

Elevar Receives FDA CRL for Liver Cancer Combination

Elevar Therapeutics, Inc. (a subsidiary of HLB Co., Ltd., 028300.KQ) received a complete response letter (CRL) regarding its application for Rivoceranib plus Camrelizumab in first-jnt line unresectable or metastatic hepatocellular carcinoma. The decision hinged on manufacturing deficiencies, not clinical data. Phase 3 CARES‑310 demonstrated a median overall survival of 23.8 months, the longest yet reported for first‑line HCC therapy, with consistent efficacy and manageable safety.

028300.KQ closed Friday’s trade at KRW 35,300.00, up 1.73 %.

<اسي>Merck Gains FDA Approval for KEYTRUDA + Padcev Combination

Merck & Co. (MRK) announced FDA approval for KEATRUDA (pembrolizumab) in combination with PADCEV (enfortumab vedotin‑ejfv), as neoadjuvant and adjuvant therapy for adults with muscle‑invasive bladder cancer (MIBC). The approvals, derived from the Phase 3 KEYNOTE‑B15 trial, represent the first PD‑1 inhibitor plus antibody‑drug conjugate (ADC) regimen authorised in MIBC, irrespective of cisplatin eligibility.

MRK closed Friday’s trading at $127.50, a 0.10 % discount.

Deals

Elutia Sells SimpliDerm to Cellution for Up to $11 M

Elutia Inc. (ELUT) finalized an agreement to sell its SimpliDerm human acellular dermal matrix line to Cellution Biologics Inc. The transaction, valued at up to $11 million, aligns with Elutia’s focus on NXT‑41x, an antibiotic‑eluting biomatrix targeting the $1.5 billion U.S. plastic and reconstructive surgery market. The deal is slated to close coffees second half of 2026.

ELUT closed Friday’s trade at $0.95.

Eli Lilly Acquires AtaiBeckley for Neuroscience Expansion

Eli Lilly and Company (LLY) announced a definitive agreement to acquire AtaiBeckley Inc. (ATAI), a clinical‑stage biopharma developing therapies for mental health disorders. The key program, BPL‑003 (mebufotenin benzoate), showed rapid and sustained depression relief in a Phase 2b study. Lilly will purchase all outstanding shares at $6.75 per share in cash, with an additional contingent value right of up to $2.50 per share.

The upfront transaction approximates $2тератрәзбd billions, with potential additional value near $1 billion, and the deal is expected to close in Q3 2026.

LLY closedcement Friday’s trade at $1,179.11, a 0.85 % increase.

Glucotrack and Lokahi Therapeutics Complete Strategic Combination

Glucotrack, Inc. (GCTK) announced the successful integration with Lokahi Therapeutics. The new entity blends Lokahi’s dual‑engine model and AI‑driven asset sourcing with Glucotrack’s technology platform, creating a scalable framework APC. Lokahi becomes the operating entity, leveraging Glucotrack’s public‑market status to facilitate capital access.

GCTK closed Friday’s trade at $0.49, down 1.60 %.

AstraZeneca Secures Global Rights to Zegfrovy

AstraZeneca (AZN) entered an exclusive licence with Dizal Pharmaceutical Co., Ltd. for Zegfrovy, an oral irreversible epidermal growth factor receptor inhibitor targeted at lung cancer patients. AZN will obtain worldwide rights to development and commercialisation of Zegfrovy, with an upfront payment of $ 盛٦٠٠ million and additional milestone payments up to $900 million.

AZN closed Friday’s trade at $168.90, a 0.23 %төнн.

Matinas BioPharma Merges with GH Power; Sells LNC Platform to Azurity Pharmaceuticals

Matinas BioPharma Holdings Inc. (MTNB) announced a strategic merger with GH Power Inc., creating a publically traded clean‑energy and green hydrogen company. Simultaneously, it agreed to divest its lipid nano‑crystal (LNC) platform and lead antifungal candidate, MAT2203, to Azurity Pharmaceuticals for an upfront $4 million and up to $17.5 million in milestone payments, plus future royalties.

MTNB closed Friday’s trade at $0.34, down 3.62 %.

Clinical Trials – Breakthroughs & Setbacks

Insmed Confirms Positive 12‑Month Data for Treprostinil Palmitil Inhalation Powder in Pulmonary Arterial Hypertension

Insmed Incorporated (INSM) reported encouraging results from its open‑label extension of treprostinil palmitil inhalation powder (TPIP), a once‑daily therapy for pulmonary arterial hypertension (PAH). Patients achieved sustained improvements across efficacy endpoints, and no new safety concerns emerged at doses up to 1,280 µg daily.

INSM closed Friday’s trading at $108.30, a 0.80 % gain.

Fractyl’s Revita Maintains Weight Loss After GLP‑1 Discontinuation

Fractyl Health, Inc. (GUTS) presented 12‑month data from the REMAIN‑1 population, demonstrating that its Revita duodenal mucosal resurfacing (DMR) system can preserve(size) weight loss post‑GLP‑1 therapy. In the mid‑point cohort, a single Revita procedure reduced weight regain by ~40 % versus sham, while 73 % of patients maintained at least 5 % total body‑weight loss at one year—a figure rising to 91 % in those undergoing full ablation.

GUTS closed Friday’s trade at $0.81, a 5.19 % decline.

Veradermics Announces Positive Phase 2 Results for VDPHL01 in Women with Pattern Hair Loss

Veradermics, Inc. (MANE) reported promising topline data from its Phase 2 study of VDPHL01, an extended‑release oral minoxidil formulation, in women with mild‑to‑moderate patternঝ baldness 手机天天中彩票. The drug was well‑tolerated and produced meaningful hair growth, with participants on a 4.5 mg daily dose recording an average increase of 22.7 hairs per square centimetre over six months. A twice‑daily regimen yielded a similar increase of 23.3 hairs per square centimetre.

MANE closed Friday’s trade at $111.32, up 5.19 %.

Biogen’s Phase 2 CELIA Study Shows Tau Reduction and Cognitive Benefit in Early Alzheimer’s Disease

Biogen Inc. (BIIB) presented data from its Phase 2 CELIA study of Diranersen, an antisense oligonucleotide targeting tau protein, at the Alzheimer’s Association International Conference 2026. The 60 mg dose yielded the most robust response, reducing cognitive decline by 42 % on ADAS‑Cog13, 50 % on MMSE, and 26 % on CDR‑SB compared to placebo.

BIIB closed Friday’s trade at $205.99, a 1.40 % decline.

Cadrenal Reports Positive Phase 2 Data for CAD‑1005 in Heparin‑Induced Thrombocytopenia

Cadrenal Therapeutics (CVKD) disclosed Phase 2 results for CAD‑1005, a selective 12‑lipoxygenase inhibitor targeting heparin‑induced thrombocytopenia. The study showed a >25 % reduction in new or worsening thrombotic events versus placebo, with no new safety signals.

CVKD closed Friday’s trade at $2.16, down 7.30 %.

GSK Decides Not to Advance Camlipixant for Chronic Cough

GSK plc (GSK) provided updates on the CALM‑1 and CALM‑2 Phase 3 trials of camlipixant in refractory chronic cough. While CALM‑1 achieved its primary endpoint, CALM‑2 failed to meet statistical significance at 50 mg BID at week 24. Consequently, GSK has chosen not to progress further development of the compound.

GSK closed Friday’s trade at $51.76, a 1.91 % decline.

Source link